Midjourney is best known for turning text prompts into images. So when the company announced it was building a full-body medical scanner and a chain of spas to go with it, the reaction was understandable confusion. This is about as far from AI-generated art as you can get.
But the Midjourney Scanner is real. The company is now officially in the medical hardware business, with a machine it says can scan your entire body in under 60 seconds. For comparison, a full-body MRI typically takes between 60 and 90 minutes. If Midjourney can pull this off, it would represent a significant shift in how routine medical imaging works.
The device works by submerging you in water at a rate of about 2 inches per second after you step onto a platform. A ring containing half a million tiny sensors, each about the size of a grain of sand, surrounds your body. Each sensor emits ultrasonic waves and picks up the ripples that bounce back. Midjourney compares it to echolocation, the system dolphins use to navigate and hunt, except here you’re surrounded by half a million of them firing from every angle simultaneously.
The result, according to the company, is a 3D map of your body down to a fraction of a millimeter. The company says it looks a lot like a traditional MRI scan, just produced at nearly a hundred times the speed.
Midjourney is not building this alone. It signed a licensing agreement with Butterfly Network in November 2025, giving it exclusive access to the company’s ultrasound-on-chip technology. Butterfly Network makes handheld ultrasound devices, and its chip technology is central to making the Scanner’s sensor ring work at this scale. The project is led by Ahmad Abbas, who joined Midjourney in late 2023 after working on the Vision Pro at Apple.
The company has laid out a fairly detailed roadmap for what comes next:
- Over the next 12 months, Midjourney will refine its algorithms, run research trials, and develop a second-generation hardware design
- The first Spa housing Scanners is planned to open in San Francisco sometime next year
- FDA approval for the Scanner’s diagnostic capabilities is a key next step
- By 2028, Midjourney plans to expand to more cities and release a third-generation machine using custom silicon for significantly better image quality
- The long-term goal is 50,000 Scanners worldwide by 2031
The spa concept is an interesting choice. Midjourney describes its vision as something “as powerful as MRI, and as casual as a trip to the spa.” That framing is deliberate. Getting a full-body scan is not something most people do regularly, partly because it’s expensive, time-consuming, and requires a referral. Making it feel like a wellness appointment rather than a hospital visit could change that behavior, especially for people who are health-conscious but not yet sick.
This fits into a broader trend of consumer health technology moving toward early detection and preventive care. Companies like Apple and Withings have been pushing wearable health monitoring for years. What Midjourney is proposing is a more clinical version of that idea, a regular snapshot of your body’s internal state rather than continuous surface-level tracking.
The company’s stated ambition is bold. “We think it’s completely possible that with enough early imaging in the future, the world could avoid 30 percent of all deaths and 50 percent of all healthcare costs,” Midjourney said in its announcement. That’s a sweeping claim, and it will face serious scrutiny from regulators, clinicians, and competitors before anything close to that scale becomes reality.
The FDA approval process alone could take years. Medical imaging devices require extensive clinical validation, and the bar for diagnostic accuracy is high. Midjourney is essentially starting from scratch in one of the most heavily regulated industries in the world, which is a very different challenge from shipping software updates to an AI image tool.
Still, the company has some real assets here. It has the engineering talent, the capital, and now a hardware partner with relevant technology. Whether it can build the clinical credibility and regulatory track record to match its ambitions is the harder question, and one that won’t be answered for several years.
